These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19927942)

  • 1. Anaphylaxis to gadolinium radiocontrast: a case report and review of the literature.
    Shepherd M; Lata S; Mani S; Fiorillo A; Kumar P
    J La State Med Soc; 2009; 161(5):282-4. PubMed ID: 19927942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.
    Knopp MV; Balzer T; Esser M; Kashanian FK; Paul P; Niendorf HP
    Invest Radiol; 2006 Jun; 41(6):491-9. PubMed ID: 16763467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anaphylactoid reaction caused by intravenous gadopentetate dimeglumine in magnetic resonance].
    Campos A; Aznar L; Alamar R; Castelló JV
    Med Clin (Barc); 1996 Feb; 106(5):197. PubMed ID: 8684023
    [No Abstract]   [Full Text] [Related]  

  • 4. Acute adverse reactions to magnetic resonance contrast media--gadolinium chelates.
    Li A; Wong CS; Wong MK; Lee CM; Au Yeung MC
    Br J Radiol; 2006 May; 79(941):368-71. PubMed ID: 16632615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profound pseudohypocalcemia due to gadolinium (Magnevist) contrast in a hemodialysis patient.
    Davenport A; Whiting S
    Am J Kidney Dis; 2006 Feb; 47(2):350-2. PubMed ID: 16431265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaphylaxis to gadobenate dimeglumine (Multihance): a case report.
    Kalogeromitros DC; Makris MP; Aggelides XS; Spanoudaki N; Gregoriou SG; Avgerinou G; Rigopoulos DG
    Int Arch Allergy Immunol; 2007; 144(2):150-4. PubMed ID: 17536224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seizure after gadolinium administration.
    Hailemeskal B; Ilogu E; Khuc K; Curry C; Kelvas M
    Radiol Technol; 1999; 70(4):387. PubMed ID: 10101755
    [No Abstract]   [Full Text] [Related]  

  • 8. Cardiac arrest caused by IV gadopentetate dimeglumine.
    Unal O; Arslan H
    AJR Am J Roentgenol; 1999 Apr; 172(4):1141. PubMed ID: 10587169
    [No Abstract]   [Full Text] [Related]  

  • 9. [Nephrogenic systemic fibrosis].
    Breitschaft A; Stahlmann R
    Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of serial monthly administration of triple-dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial.
    Wolansky LJ; Haghighi MH; Sevdalis E; Cook SD; Sethi N; Liu J; Joseph G; Tulloch K; Cadavid D
    J Neuroimaging; 2005 Jul; 15(3):289-90. PubMed ID: 15951416
    [No Abstract]   [Full Text] [Related]  

  • 11. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.
    Bauner KU; Reiser MF; Huber AM
    Invest Radiol; 2009 Feb; 44(2):95-104. PubMed ID: 19077911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance contrast agents for neuroimaging. Safety issues.
    Carr JJ
    Neuroimaging Clin N Am; 1994 Feb; 4(1):43-54. PubMed ID: 8130951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine.
    Shellock FG; Parker JR; Pirovano G; Shen N; Venetianer C; Kirchin MA; Spinazzi A
    J Magn Reson Imaging; 2006 Dec; 24(6):1378-85. PubMed ID: 17078095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudohypocalcemia after magnetic resonance imaging with gadolinium in patients with cirrhosis.
    Kefalas CH; Murray NG; Aguanno JJ; Dockery WD; Weinstein JS; Anderson K; Klintmalm GB
    Liver Transpl; 2004 Jan; 10(1):136-40. PubMed ID: 14755791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.
    Knopp MV; Runge VM; Essig M; Hartman M; Jansen O; Kirchin MA; Moeller A; Seeberg AH; Lodemann KP
    Radiology; 2004 Jan; 230(1):55-64. PubMed ID: 14695387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
    Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
    Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine.
    Anzalone N; Gerevini S; Scotti R; Vezzulli P; Picozzi P
    Acta Radiol; 2009 Oct; 50(8):933-40. PubMed ID: 19626475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-reactive protein levels and clinical symptoms following gadolinium administration in hemodialysis patients.
    Schieren G; Tokmak F; Lefringhausen L; van Bracht M; Perings C; Willers R; Günsel A; Kemper F; Wiesmüller GA; Rump LC
    Am J Kidney Dis; 2008 Jun; 51(6):976-86. PubMed ID: 18501785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor.
    Moreno-Romero JA; Segura S; Mascaró JM; Cowper SE; Julià M; Poch E; Botey A; Herrero C
    Br J Dermatol; 2007 Oct; 157(4):783-7. PubMed ID: 17627792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gadopentetate dimeglumine-enhanced three-dimensional MR-angiography: dosing, safety, and efficacy.
    Goyen M; Debatin JF
    J Magn Reson Imaging; 2004 Mar; 19(3):261-73. PubMed ID: 14994293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.